Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells

European Journal of Pharmacology

Volumn 368, Issue 1, 1999, Pages 89-94

  Tahara, Atsuo ^a   Saito, Masayuki ^a   Tsukada, Junko ^a   Ishii, Noe ^a   Tomura, Yuichi ^a   Wada, Koh Ichi ^a   Kusayama, Toshiyuki ^a   Yatsu, Takeyuki ^a   Uchida, Wataru ^a   Tanaka, Akihiro ^a  

^a Inst for Drug Discovery Research   (Japan)

Author keywords

Smooth muscle cell, vascular; Vasopressin; VEGF (vascular endothelial growth factor)

Indexed keywords

CONIVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; N [4 (TERT BUTYLCARBAMOYL) 2 METHOXYBENZENESULFONYL] 5 ETHOXY 3 SPIRO[4 (2 MORPHOLINOETHOXY)CYCLOHEXANE]INDOL 2 ONE; RELCOVAPTAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOGENESIS; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0033014807     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00004-7     Document Type: Article

References (24)

1. Bobik A., Campbell J.H. Vascular derived growth factors: cell biology, pathophysiology, and pharmacology. Pharmacol. Rev. 45:1993;1-42.
2. Caramelo C., Okada K., Tsai P., Schrier R.W. Phorbol esters and arginine vasopressin in vascular smooth muscle cell activation. Am. J. Physiol. 256:1989;F875-F881.
3. De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
4. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13:1992;18-32.
5. Geisterfer A.A., Owens G.K. Arginine vasopressin-induced hypertrophy of cultured rat aortic smooth muscle cells. Hypertension. 14:1989;413-420.
6. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
7. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrare N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
8. Lincoln J., Loesch A., Burnstock G. Localization of vasopressin, serotonin and angiotensin II in endothelial cells of the renal and mesenteric arteries of the rat. Cell Tissue Res. 259:1990;341-344.
9. Loesch A., Bodin P., Burnstock G. Colocalization of endothelin, vasopressin and serotonin in cultured endothelial cells of rabbit aorta. Peptides. 12:1991;1095-1103.
10. Nauck M., Roth M., Tamm M., Eickelberg O., Wieland H., Stulz P., Perruchoud A.P. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am. J. Respir. Cell Mol. Biol. 16:1997;398-406.
11. Pedram A., Razandi M., Hu R.M., Levin E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J. Biol. Chem. 272:1997;17097-17103.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
13. Schwartz S.M., Campbell G.R., Campbell J.H. Replication of smooth muscle cells in vascular disease. Circ. Res. 58:1986;427-444.
14. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 50:1990;1774-1778.
15. 1a receptors. J. Clin. Invest. 92:1993;224-231.
16. 1a antagonist, on human vascular smooth muscle cells. Am. J. Physiol. 268:1995;H404-H410.
17. 2 receptor antagonist. J. Clin. Invest. 98:1996;2729-2738.
18. Simon J.S., Brody M.J., Kasson B.G. Characterization of a vasopressin-like peptide in rat and bovine blood vessels. Am. J. Physiol. 262:1992;H799-H805.
19. Tahara A., Tomura Y., Wada K., Kusayama T., Tsukada J., Ishii N., Yatsu T., Uchida W., Tanaka A. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells. J. Cardiovasc. Pharmacol. 30:1997;759-766.
20. 2 receptor antagonist, in vitro and in vivo. J. Pharmacol. Exp. Ther. 282:1997;301-308.
21. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187:1992;1579-1586.
22. Tischer E., Mitchell R., Hartman T., Sliva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. J. Biol. Chem. 266:1991;11947-11954.
23. Tsai J.C., Goldman C.K., Gillespie G.Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg. 82:1995;864-873.
24. Williams B., Baker A.Q., Gallacher B., Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension. 25:1995;913-917.